Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial update evaluating the safety and efficacy of daily 18 µg formoterol (9 µg twice daily) in Japanese chronic obstructive pulmonary disease patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Formoterol (formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2013-01-04